Trastuzumab
SRC Inhibition Overcomes Trastuzumab Resistance in HER2-Overexpressing Breast Cancers.
Cancer Discov. 2011 Jun;1(1):11
Authors:
PMID: 22586311 [PubMed - in process]
Re: Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria.
J Natl Cancer Inst. 2012 May 10;
Authors: Wolff AC, Hammond ME, Hayes DF
PMID: 22581974 [PubMed – as s…
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Oncotarget. 2012 May 4;
Authors: Cu…
Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series.
J Oncol. 2012;2012:198412
Authors: Di Lauro V, Torrisi E, Bidoli E, Quitadamo D, Cecco S,…
Trastuzumab Combined with Docetaxel-Based Regimens in Previously Treated Metastatic Gastric Cancer Patients with HER2 Over-Expression.
Hepatogastroenterology. 2012 Apr 25;59(120)
Authors: Dai GH, Shi Y, Chen L, Lv YL, Zhong …
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunothe…
DOTAGA-Trastuzumab. A new antibody conjugate targeting HER2/neu antigen for diagnostic purposes.
Bioconjug Chem. 2012 Apr 23;
Authors: Moreau M, Raguin O, Vrigneaud JM, Collin B, Bernhard C, Tizon X, Boschetti F, Duchamp O, …
Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations.
Clin Med Insights Oncol. 2012;6:179-87
Authors: Jeyakumar A, Younis T
Abstract
Trastuzumab is a recombinant humani…
Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells.
Int J Cancer. 2012 Apr 17;
Authors: Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp UR…
Elevated HER2 Extracellular Domain Level in Primary Breast Cancer with HER2 Overexpression Predicts Early Failure of Adjuvant Trastuzumab.
Anticancer Res. 2012 Apr;32(4):1429-33
Authors: Thureau S, Clatot F, Laberge-LE-Coute…